对酒精使用障碍药物治疗试验的终点
Malia A Belnap1, Kaitlin R McManus2, Erica N Grodin2,3
1Neuroscience Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA.
Pharmaceutical medicine
|July 5, 2024
概括
酒精使用障碍 (AUD) 药物治疗试验的新终点正在出现. 这些新的措施,包括降低危害和生物标记,可以更好地捕捉超越戒断的AUD复杂性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
- 成 药物 药物 药物 药物
背景情况:
- 酒精使用障碍 (AUD) 是一个重要的健康问题,药物疗法未得到充分利用.
- 目前FDA批准的AUD药物包括dissulfiram,acamprosate和naltrexone.
- 对于AUD药物治疗试验的现有治疗结果测量有局限性.
研究的目的:
- 探索用于研究AUD药物治疗的临床试验的新型终点.
- 讨论减少危害的潜力,生物标志物和以患者为导向的结果.
主要方法:
- 审查AUD药物治疗研究中的当前和新兴终点.
- 讨论传统与新型结果措施的讨论.
- 对新终点的有效性和可靠性的考虑.
主要成果:
- 传统的AUD试验终点依赖于自我报告的戒断或减少大量饮酒的日子.
- 新的终点包括世卫组织风险饮酒水平降低 (降低危害),客观生物标志物和以患者为导向的结果.
- 像NIAAA恢复定义这样的新兴框架提供了更广泛的视角.
结论:
- 新的终点为改善对AUD药物疗法的评估提供了有希望的机会.
- 更广泛的终点利用可以更好地反映AUD的多面性质.
- 证明有效性和可靠性对于采用新的终点至关重要.
相关概念视频
CNS Depressants: Alcohol and Nicotine
201
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
201
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Psychosis: Goals of Pharmacotherapy
119
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
119
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Substance Use Disorders Affecting Sleep
164
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
164


